International Journal of Hematology

, Volume 82, Issue 3, pp 196–200 | Cite as

Immune Pathophysiology of Aplastic Anemia

  • Shinji Nakao
  • Xingmin Feng
  • Chiharu Sugimori


Acquired aplastic anemia (AA) is considered an immune-mediated disease because approximately 70% of AA patients improve with immunosuppressive therapy. However, little is known about the inciting antigens or the mechanisms responsible for the destruction of hematopoietic stem cells by immune system attack. Recent advances in immunologic techniques have promoted our understanding of the pathogenesis of AA and have provided evidence that AA is an organ-specific T-cell-mediated disease localized in the bone marrow. Moreover, antibody screening of patients’ serum with a complementary DNA library derived from hematopoietic cells has identified several proteins as candidate autoantigens in AA.

Key words

Aplastic anemia T-cell repertoire Autoantigen Paroxysmal nocturnal hemoglobinuria 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Young NS, Maciejewski J. The pathophysiology of acquired aplas-tic anemia. N Engl J Med. 1997;336:1365–1372.CrossRefPubMedGoogle Scholar
  2. 2.
    Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylpred-nisolone with or without cyclosporine: the German Aplastic Anemia Study Group. N Engl J Med. 1991;324:1297–1304.CrossRefPubMedGoogle Scholar
  3. 3.
    Bacigalupo A, Bruno B, Saracco P, et al, for the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood. 2000;95:1931–1934.PubMedGoogle Scholar
  4. 4.
    Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049–2054.PubMedGoogle Scholar
  5. 5.
    Safadi R, Or R, Ilan Y, et al. Lack of known hepatitis virus in hepatitis-associated aplastic anemia and outcome after bone marrow transplantation. Bone Marrow Transplant. 2001;27:183–190.CrossRefPubMedGoogle Scholar
  6. 6.
    Nimer SD, Ireland P, Meshkinpour A, Frane M. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood. 1994;84:923–927.PubMedGoogle Scholar
  7. 7.
    Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100:1570–1574.PubMedGoogle Scholar
  8. 8.
    Sugimori C, Chuhjo T, Wang H, Feng X, Nakao S. Roles of HLA-DR15 alleles in the immune mechanisms of acquired aplastic anemia: methods of contribution differ between DRB1*1501 and DRB1*1502 [abstract]. Blood. 2003;102:508a.Google Scholar
  9. 9.
    Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994;84:4257–4261.PubMedGoogle Scholar
  10. 10.
    Maciejewski JP, Follmann D, Nakamura R, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemo-globinuria and the PNH/aplastic anemia syndrome. Blood. 2001;98:3513–3519.CrossRefPubMedGoogle Scholar
  11. 11.
    Sprent J, Surh CD, Agus D, Hurd M, Sutton S, Heath WR. Profound atrophy of the bone marrow reflecting major histocompatibility complex class II-restricted destruction of stem cells by CD4+ cells. J Exp Med. 1994;180:307–317.CrossRefPubMedGoogle Scholar
  12. 12.
    Zeng W, Nakao S, Takamatsu H, et al. Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood. 1999;93:3008–3016.PubMedGoogle Scholar
  13. 13.
    Zeng W, Maciejewski JP, Chen G, Young NS. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest. 2001;108:765–773.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kook H, Risitano AM, Zeng W, et al. Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood. 2002;99:3668–3675.CrossRefPubMedGoogle Scholar
  15. 15.
    Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR ß-CDR3 sequencing. Lancet. 2004;364:355–364.CrossRefPubMedGoogle Scholar
  16. 16.
    Viglietta V, Kent SC, Orban T, Hafler DA. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest. 2002;109:895–903.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Gran B, Rostami A. T cells, cytokines, and autoantigens in multiple sclerosis. Curr Neurol Neurosci Rep. 2001;1:263–270.CrossRefPubMedGoogle Scholar
  18. 18.
    Hirano N, Butler MO, Von Bergwelt-Baildon MS, et al. Autoanti-bodies frequently detected in patients with aplastic anemia. Blood. 2003;102:4567–4575.CrossRefPubMedGoogle Scholar
  19. 19.
    Feng X, Chuhjo T, Sugimori C, et al. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2004;104:2425–2431.CrossRefPubMedGoogle Scholar
  20. 20.
    Kagan WA, Ascensao JA, Pahwa RN, et al. Aplastic anemia: presence in human bone marrow of cells that suppress myelopoiesis. Proc NatlAcad Sci USA. 1976;73:2890–2894.CrossRefGoogle Scholar
  21. 21.
    Zoumbos NC, Gascon P, Djeu JY, Young NS. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc NatlAcad Sci USA. 1985;82:188–192.CrossRefGoogle Scholar
  22. 22.
    Nakao S, Yamaguchi M, Shiobara S, et al. Interferon-gamma gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia. Blood. 1992;79:2532–2535.PubMedGoogle Scholar
  23. 23.
    Nistico A, Young NS. gamma-Interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med. 1994;120:463–469.CrossRefPubMedGoogle Scholar
  24. 24.
    Hara T, Ando K, Tsurumi H, Moriwaki H. Excessive production of tumor necrosis factor-alpha by bone marrow T lymphocytes is essential in causing bone marrow failure in patients with aplastic anemia. Eur J Haematol. 2004;73:10–16.CrossRefPubMedGoogle Scholar
  25. 25.
    Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-α antibody therapy. Blood. 2002;100:474–482.CrossRefPubMedGoogle Scholar
  26. 26.
    Stasi R, Amadori S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol. 2002;116:334–337.CrossRefPubMedGoogle Scholar
  27. 27.
    Maciejewski JP, Risitano AM, Sloand EM, et al. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)- Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol. 2002;117:119–126.CrossRefPubMedGoogle Scholar
  28. 28.
    Rosenfeld C, Bedell C. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. Leuk Res. 2002;26:721–724.CrossRefPubMedGoogle Scholar
  29. 29.
    Nakao S, Takami A, Takamatsu H, et al. Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood. 1997;89:3691–3699.PubMedGoogle Scholar
  30. 30.
    Takami A, Zeng W, Wang H, Matsuda T, Nakao S. Cytotoxicity against lymphoblastoid cells mediated by a T-cell clone from an aplastic anaemia patient: role of CD59 on target cells. Br J Haematol. 1999;107:791–796.CrossRefPubMedGoogle Scholar
  31. 31.
    Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol. 2001;29:1270–1277.CrossRefPubMedGoogle Scholar
  32. 32.
    Wang H, Chuhjo T, Yamazaki H, et al. Relative increase of granu-locytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis. Eur J Haematol. 2001;66:200–205.CrossRefPubMedGoogle Scholar
  33. 33.
    Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002;100:3897–3902.CrossRefPubMedGoogle Scholar
  34. 34.
    Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglo-binuria genotype and phenotype are present in normal individuals. Proc NatlAcad Sci USA. 1999;96:5209–5214.CrossRefGoogle Scholar
  35. 35.
    Murakami Y, Kosaka H, Maeda Y, et al. Inefficient response of T lymphocytes to glycosylphosphatidylinositol anchor-negative cells: implications for paroxysmal nocturnal hemoglobinuria. Blood. 2002;100:4116–4122.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2005

Authors and Affiliations

  1. 1.Cellular Transplantation BiologyKanazawa University Graduate School of Medical ScienceKanazawa, IshikawaJapan

Personalised recommendations